Combined with the last dividend raise by +3.3% in December 2024, building upon the 10Y growth profile at +5.27%, we believe ...

BMY stock offers value with a sub-7x P/E, 6% dividend yield, and strong earnings. Discover why it’s a compelling buy despite ...

Garmin today announced SmartCharts, a dynamic aviation charting solution that will provide pilots with a simplified and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bristol Myers BMY announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) ...

AI's fourth-quarter fiscal 2025 results reflect strong subscription revenues, driven by strong traction with its ...

As workforce dynamics evolve at a torrid pace, HR and payroll professionals must be adept at building the business case for change to ensure their organization's labor and employee engagement ...

Shares of Prothena PRTA tumbled 22.5% in after-hours trading on May 23 after it announced the discontinuation of the ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...